Aclidinium Bromide Twice Daily for the Treatment of Chronic Obstructive Pulmonary Disease: A Review

@article{Jones2013AclidiniumBT,
  title={Aclidinium Bromide Twice Daily for the Treatment of Chronic Obstructive Pulmonary Disease: A Review},
  author={P. Jones},
  journal={Advances in Therapy},
  year={2013},
  volume={30},
  pages={354-368}
}
  • P. Jones
  • Published 2013
  • Medicine
  • Advances in Therapy
  • The inhaled, long-acting muscarinic antagonist, aclidinium bromide, was indicated in July 2012 in Europe and the USA for the maintenance of bronchodilator treatment to relieve symptoms of chronic obstructive pulmonary disease (COPD) in adults. Although initially investigated as a once-daily agent, a lower than expected improvement in trough forced expiratory volume over 1 s prompted re-evaluation as a twice-daily (b.i.d.) regimen. The dose approved for use in Europe, 400 μg b.i.d., achieved… CONTINUE READING
    COPD: JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    • Yong Zoua, Jian Xiaoa, Dan Hui Yanga, Jun Lib, Qiong Chena
    • 2016

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 42 REFERENCES
    Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
    • 77
    • PDF
    Long-term efficacy of twice-daily aclidinium bromide in COPD patients: A one-year study
    • 1
    • Highly Influential
    Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study
    • 175
    • PDF